Findings

What do systematic reviews say?

40 questions · 40 findings · 4 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 6 · 15%GRADE not reported 0 · 0%Very low 8 · 20%Low 17 · 42.5%Moderate 8 · 20%High 1 · 2.5%

Oral 5‐aminosalicylic acid vs 5‐aminosalicylic acid (5‐ASA) (mesalazine)

Serious adverse events · Patients with quiescent ulcerative colitis

Oral 5‐aminosalicylic acid showed no clear difference in serious adverse events compared with comparator 5‐aminosalicylic acid formulation (low certainty).

1 finding from 1 review

Oral 5‐aminosalicylic acid for maintenance of remission in ulcerative colitis 2020 · Cochrane Headline outcomes only
RR 0.56 [0.14, 2.22]
1 study · 95 participants
Low

Oral 5‐aminosalicylic acid vs 5‐aminosalicylic acid (5‐ASA) (mesalazine)

Withdrawals due to adverse events · Patients with quiescent ulcerative colitis

It is very uncertain whether oral 5‐aminosalicylic acid changes withdrawal due to adverse events compared with comparator 5‐aminosalicylic acid formulation (very low certainty).

1 finding from 1 review

Oral 5‐aminosalicylic acid for maintenance of remission in ulcerative colitis 2020 · Cochrane Headline outcomes only
RR 1.25
5 studies · 457 participants
Very low

Oral 5‐aminosalicylic acid vs placebo

Adverse events · Patients with quiescent ulcerative colitis

Oral 5‐aminosalicylic acid showed no clear difference in adverse events compared with placebo (moderate certainty).

1 finding from 1 review

Oral 5‐aminosalicylic acid for maintenance of remission in ulcerative colitis 2020 · Cochrane Headline outcomes only
RR 0.93 [0.73, 1.18]
5 studies · 1132 participants
Moderate

Oral 5‐aminosalicylic acid vs sulfasalazine

Serious adverse events · Patients with quiescent ulcerative colitis

The review found no eligible studies for this question.

1 finding from 1 review

Oral 5‐aminosalicylic acid for maintenance of remission in ulcerative colitis 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Oral 5‐aminosalicylic acid vs placebo

Serious adverse events · Patients with quiescent ulcerative colitis

Oral 5‐aminosalicylic acid showed no clear difference in serious adverse events compared with placebo (low certainty).

1 finding from 1 review

Oral 5‐aminosalicylic acid for maintenance of remission in ulcerative colitis 2020 · Cochrane Headline outcomes only
RR 0.6 [0.19, 1.84]
3 studies · 826 participants
Low

Oral 5‐ASA vs SASP

Adverse events · Patients with active mild to moderate ulcerative colitis

Oral 5‐ASA probably leads to lower adverse events compared with SASP (moderate certainty).

1 finding from 1 review

Oral 5‐aminosalicylic acid for induction of remission in ulcerative colitis 2020 · Cochrane Headline outcomes only
RR 0.48 [0.36, 0.63]
12 studies · 909 participants
Moderate

Oral 5‐ASA vs 5‐aminosalicylic acid (5‐ASA) (mesalazine)

Adverse events · Patients with active mild to moderate ulcerative colitis

Oral 5‐ASA showed no clear difference in adverse events compared with comparator 5‐ASA (moderate certainty).

1 finding from 1 review

Oral 5‐aminosalicylic acid for induction of remission in ulcerative colitis 2020 · Cochrane Headline outcomes only
RR 1.01 [0.92, 1.12]
9 studies · 1576 participants
Moderate

Oral 5‐ASA vs placebo

Adverse events · Patients with active mild to moderate ulcerative colitis

Oral 5‐ASA showed no clear difference in adverse events compared with placebo (high certainty).

1 finding from 1 review

Oral 5‐aminosalicylic acid for induction of remission in ulcerative colitis 2020 · Cochrane Headline outcomes only
RR 0.95 [0.85, 1.07]
8 studies · 1218 participants
High

Oral 5‐ASA vs SASP

Serious adverse events · Patients with active mild to moderate ulcerative colitis

Oral 5‐ASA showed no clear difference in serious adverse events compared with SASP (low certainty).

1 finding from 1 review

Oral 5‐aminosalicylic acid for induction of remission in ulcerative colitis 2020 · Cochrane Headline outcomes only
RR 1.36 [0.28, 6.52]
2 studies · 107 participants
Low

Oral 5‐ASA vs 5‐aminosalicylic acid (5‐ASA) (mesalazine)

Serious adverse events · Patients with active mild to moderate ulcerative colitis

Oral 5‐ASA showed no clear difference in serious adverse events compared with comparator 5‐ASA (low certainty).

1 finding from 1 review

Oral 5‐aminosalicylic acid for induction of remission in ulcerative colitis 2020 · Cochrane Headline outcomes only
RR 0.59 [0.22, 1.56]
4 studies · 677 participants
Low

Oral 5‐ASA vs placebo

Serious adverse events · Patients with active mild to moderate ulcerative colitis

Oral 5‐ASA showed no clear difference in serious adverse events compared with placebo (low certainty).

1 finding from 1 review

Oral 5‐aminosalicylic acid for induction of remission in ulcerative colitis 2020 · Cochrane Headline outcomes only
RR 0.53 [0.18, 1.56]
4 studies · 746 participants
Low

Oral 5‐ASA vs SASP

Withdrawals due to adverse events · Patients with active mild to moderate ulcerative colitis

Oral 5‐ASA probably leads to lower withdrawal due to adverse events compared with SASP (moderate certainty).

1 finding from 1 review

Oral 5‐aminosalicylic acid for induction of remission in ulcerative colitis 2020 · Cochrane Headline outcomes only
RR 0.4 [0.24, 0.68]
10 studies · 640 participants
Moderate

Oral 5‐ASA vs 5‐aminosalicylic acid (5‐ASA) (mesalazine)

Withdrawals due to adverse events · Patients with active mild to moderate ulcerative colitis

Oral 5‐ASA showed no clear difference in withdrawal due to adverse events compared with comparator 5‐ASA (moderate certainty).

1 finding from 1 review

Oral 5‐aminosalicylic acid for induction of remission in ulcerative colitis 2020 · Cochrane Headline outcomes only
RR 0.94 [0.57, 1.54]
9 studies · 1489 participants
Moderate

Oral 5‐ASA vs placebo

Withdrawals due to adverse events · Patients with active mild to moderate ulcerative colitis

Oral 5‐ASA probably leads to lower withdrawal due to adverse events compared with placebo (moderate certainty).

1 finding from 1 review

Oral 5‐aminosalicylic acid for induction of remission in ulcerative colitis 2020 · Cochrane Headline outcomes only
RR 0.72 [0.54, 0.97]
13 studies · 2372 participants
Moderate

Once daily dosing vs conventional dosing

Adverse events · Patients with active mild to moderate ulcerative colitis

Once daily dosing showed no clear difference in adverse events compared with conventional dosing (moderate certainty).

1 finding from 1 review

Oral 5‐aminosalicylic acid for induction of remission in ulcerative colitis 2020 · Cochrane Headline outcomes only
RR 1.02 [0.89, 1.18]
4 studies · 1586 participants
Moderate